Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982122010> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2982122010 abstract "Abstract Background Quinidine at high-dose is used in patients with Brugada Syndrome (BrS), but its efficacy to prevent life-threatening arrhythmic events (LAE) in BrS is unproven and its use is limited by side effects. Objective We assessed whether low-dose quinidine in BrS patients reduces: 1) the occurrence of a first LAE; 2) the arrhythmic burden in the high-risk group of cardiac arrest survivors. Methods We first compared the clinical course of 53 BrS patients treated with quinidine to that of 441 untreated controls, matched by sex, age, and symptoms. Furthermore, we calculated the annual incidence of LAEs off- and on-quinidine in 123 BrS patients who had survived a cardiac arrest. Results First, we compared the clinical course of 53 BrS patients treated with quinidine (i.e. “cases”: 89% males, median age 40 years) to that of 441 untreated, clinically-matched BrS patients (i.e. “controls”: 91% males, median age 41 years) present in our database of patients with inherited arrhythmias. Cases received quinidine (median dose of 450 mg per day) for 5.0±3.7 years. Quinidine was interrupted in only 3/53 cases (6%) for side effects and it conferred a nonsignificant reduction of the risk of a first LAE in cases versus controls (HR 0.74, 95% CI 0.22–2.48, P=0.62). Secondly, we calculated the annual recurrence of LAE off- and on-quinidine in 123 BrS cardiac arrest survivors, 27 of whom were treated with quinidine for 7.0±3.5 years. The annual rate of recurrent LAEs decreased significantly from 14.7% while off-quinidine to 3.9% while on-quinidine (P=0.03). Notably, recurrent life-threatening arrhythmic events were recorded in 4/27 (15%) symptomatic patients while on-quinidine. Conclusion We demonstrated for the first time in the long-term that low-dose quinidine reduces the recurrence of life-threatening arrhythmias in symptomatic BrS patients, with few side effects. Remarkably, about one-fifth of symptomatic patients experience life-threatening arrhythmias while on-treatment, suggesting that quinidine cannot replace implantable defibrillators in high-risk subjects." @default.
- W2982122010 created "2019-11-01" @default.
- W2982122010 creator A5006513124 @default.
- W2982122010 creator A5008966758 @default.
- W2982122010 creator A5010776107 @default.
- W2982122010 creator A5018609711 @default.
- W2982122010 creator A5021196395 @default.
- W2982122010 creator A5029382158 @default.
- W2982122010 creator A5048497181 @default.
- W2982122010 creator A5050794998 @default.
- W2982122010 creator A5051814294 @default.
- W2982122010 creator A5053012588 @default.
- W2982122010 creator A5065720395 @default.
- W2982122010 creator A5068361920 @default.
- W2982122010 date "2019-10-01" @default.
- W2982122010 modified "2023-09-23" @default.
- W2982122010 title "6081Efficacy and limitations of quinidine therapy in patients with Brugada Syndrome" @default.
- W2982122010 doi "https://doi.org/10.1093/eurheartj/ehz746.0125" @default.
- W2982122010 hasPublicationYear "2019" @default.
- W2982122010 type Work @default.
- W2982122010 sameAs 2982122010 @default.
- W2982122010 citedByCount "0" @default.
- W2982122010 crossrefType "journal-article" @default.
- W2982122010 hasAuthorship W2982122010A5006513124 @default.
- W2982122010 hasAuthorship W2982122010A5008966758 @default.
- W2982122010 hasAuthorship W2982122010A5010776107 @default.
- W2982122010 hasAuthorship W2982122010A5018609711 @default.
- W2982122010 hasAuthorship W2982122010A5021196395 @default.
- W2982122010 hasAuthorship W2982122010A5029382158 @default.
- W2982122010 hasAuthorship W2982122010A5048497181 @default.
- W2982122010 hasAuthorship W2982122010A5050794998 @default.
- W2982122010 hasAuthorship W2982122010A5051814294 @default.
- W2982122010 hasAuthorship W2982122010A5053012588 @default.
- W2982122010 hasAuthorship W2982122010A5065720395 @default.
- W2982122010 hasAuthorship W2982122010A5068361920 @default.
- W2982122010 hasConcept C126322002 @default.
- W2982122010 hasConcept C164705383 @default.
- W2982122010 hasConcept C177713679 @default.
- W2982122010 hasConcept C2777382798 @default.
- W2982122010 hasConcept C2780339425 @default.
- W2982122010 hasConcept C71924100 @default.
- W2982122010 hasConceptScore W2982122010C126322002 @default.
- W2982122010 hasConceptScore W2982122010C164705383 @default.
- W2982122010 hasConceptScore W2982122010C177713679 @default.
- W2982122010 hasConceptScore W2982122010C2777382798 @default.
- W2982122010 hasConceptScore W2982122010C2780339425 @default.
- W2982122010 hasConceptScore W2982122010C71924100 @default.
- W2982122010 hasLocation W29821220101 @default.
- W2982122010 hasOpenAccess W2982122010 @default.
- W2982122010 hasPrimaryLocation W29821220101 @default.
- W2982122010 hasRelatedWork W1546355967 @default.
- W2982122010 hasRelatedWork W2064198792 @default.
- W2982122010 hasRelatedWork W2099670386 @default.
- W2982122010 hasRelatedWork W2119087804 @default.
- W2982122010 hasRelatedWork W2315490779 @default.
- W2982122010 hasRelatedWork W2331093676 @default.
- W2982122010 hasRelatedWork W2399978114 @default.
- W2982122010 hasRelatedWork W2409289692 @default.
- W2982122010 hasRelatedWork W2409298134 @default.
- W2982122010 hasRelatedWork W2409999559 @default.
- W2982122010 hasRelatedWork W2417253407 @default.
- W2982122010 hasRelatedWork W2417915863 @default.
- W2982122010 hasRelatedWork W2463392107 @default.
- W2982122010 hasRelatedWork W2597940648 @default.
- W2982122010 hasRelatedWork W2724972568 @default.
- W2982122010 hasRelatedWork W2794176649 @default.
- W2982122010 hasRelatedWork W2802419081 @default.
- W2982122010 hasRelatedWork W2941743000 @default.
- W2982122010 hasRelatedWork W2943896152 @default.
- W2982122010 hasRelatedWork W3180289836 @default.
- W2982122010 isParatext "false" @default.
- W2982122010 isRetracted "false" @default.
- W2982122010 magId "2982122010" @default.
- W2982122010 workType "article" @default.